|  |  |  |
| --- | --- | --- |
|  | **All PD patients**  **(N=63)**  **r** | **PD-MCI**  **(N=23)**  **r** |
| Correlation of ISAcog with: |  |  |
| age | -0.111 | 0.358 |
| Education | 0.141 | 0.184 |
| Disease duration | -0.130 | -0.124 |
| UPDRS-III | -0.228 | -0.360 |
| LEDD | -0.083 | -0.223 |
| BDI-2 | 0.300\* | 0.088 |
| Executive functions | 0.412\*\*\* | 0.128 |
| Memory | 0.287\* | 0.179 |
| Language | 0.279\* | 0.408 |
| Visual-spatial abilities | 0.354\*\*\* | 0.189 |
| Attention | 0.199 | -0.228 |

**Table S4:** Results of Spearman correlation analysis between ISAcog and clinical data in all PD patients and PD-MCI.

Abbreviations: PD, Parkinson’s disease; PD-MCI: patient with mild cognitive impairment; ISAcog, impaired self-awareness of cognitive deficits; UPDRS-III, Unified Parkinson’s disease Rating Scale; LEDD, Levodopa equivalent daily dose; BDI-2, Beck Depression Inventory-2.

\* p<.05, \*\* p<.01, \*\*\*p<.001